Completed PHASE2 INTERVENTIONAL 1-arm NCT00403130

Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer

Phase II Open Label Study of Gemcitabine, Paclitaxel and Bevacizumab Combination as First Line Treatment for Metastatic Breast Cancer

Sponsor: Eli Lilly and Company

Conditions Breast Cancer Metastatic Breast Cancer

Interventions Bevacizumab Gemcitabine Paclitaxel

Updated 8 times since 2017 Last updated: Jan 30, 2019 Started: Feb 28, 2006 Primary completion: Sep 30, 2010 Completion: Nov 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00403130, this PHASE2 trial focuses on Breast Cancer and Metastatic Breast Cancer and remains completed. Sponsored by Eli Lilly and Company, it has been updated 8 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Mar 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Mar 2019 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

May 2017 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — May 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company
Genentech, Inc.
George Albert Fisher

Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stanford, United States